Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a game app boost language in kids with autism?

NCT ID NCT07326423

Symptom relief Sponsor: ImagiRation, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a gamified app called MITA designed to improve language and thinking skills in children with autism aged 2 to 5. Sixty children will be randomly assigned to either use the app alongside their usual therapy or continue with standard care alone. The goal is to see if the app leads to greater improvements in developmental milestones and autism severity scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mental Imagery Therapy for Autism (MITA) app
What this could lead to
If it works, this could provide a fun, accessible way to boost language and cognitive skills in young children with autism.
What could go wrong
This is a small early-stage trial with only 60 children, so results may not apply to all. The app is a supplement, not a standalone treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

2 to 5 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age 2 and 5 years at the time of enrollment * diagnosis of ASD confirmed by a study investigator who was experienced in ASD diagnosis. Exclusion Criteria: * a neurodevelopmental disorder of known etiology (e.g., fragile X syndrome) * significant sensory or motor impairment, * major physical problems such as a chronic serious health condition, * seizures at time of entry. Children who developed seizures during the course of the study were not excluded. * use of psychoactive medications, * history of a serious head injury and/or neurologic disease, * alcohol or drug exposure during the prenatal period, * CARS-2 total score \> 48 (severe ASD).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial septal defect autism autism spectrum disorder intellectual disability Language

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASD

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Espacosomare

    Foz do Iguaçu, Paraná, 85865-370, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.